Michael M Lederman Selected Research

HIV Infections (HIV Infection)

1/2021	Markers of T Cell Exhaustion and Senescence and Their Relationship to Plasma TGF-β Levels in Treated HIV+ Immune Non-responders.
1/2019	HIV infection is associated with elevated biomarkers of immune activation in Ugandan adults with pneumonia.
1/2019	Pneumoproteins are associated with pulmonary function in HIV-infected persons.
1/2019	Soluble Urokinase Plasminogen Activator Receptor Is Predictive of Non-AIDS Events During Antiretroviral Therapy-mediated Viral Suppression.
1/2019	Altered Lipidome Composition Is Related to Markers of Monocyte and Immune Activation in Antiretroviral Therapy Treated Human Immunodeficiency Virus (HIV) Infection and in Uninfected Persons.
1/2018	Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection.
1/2018	Lymphoid tissue fibrosis is associated with impaired vaccine responses.
1/2018	Telmisartan Therapy Does Not Improve Lymph Node or Adipose Tissue Fibrosis More Than Continued Antiretroviral Therapy Alone.
1/2018	Effect of IL-7 Therapy on Phospho-Ribosomal Protein S6 and TRAF1 Expression in HIV-Specific CD8 T Cells in Patients Receiving Antiretroviral Therapy.
1/2017	CD161 Expression on Mucosa-Associated Invariant T Cells is Reduced in HIV-Infected Subjects Undergoing Antiretroviral Therapy Who Do Not Recover CD4+ T Cells.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael M Lederman Research Topics

Disease

68	HIV Infections (HIV Infection) 01/2021 - 04/2002
41	Infections 10/2019 - 02/2002
38	Inflammation (Inflammations) 01/2022 - 10/2010
29	Acquired Immunodeficiency Syndrome (AIDS) 03/2022 - 01/2002
17	Disease Progression 03/2022 - 04/2002
12	Viremia 01/2022 - 09/2003
6	Coinfection 01/2017 - 02/2003
5	Cardiovascular Diseases (Cardiovascular Disease) 01/2020 - 02/2014
5	Immune Reconstitution Inflammatory Syndrome 02/2016 - 07/2010
4	Atherosclerosis 01/2020 - 10/2013
4	Virus Diseases (Viral Diseases) 01/2017 - 01/2003
3	Atherosclerotic Plaque (Atheroma) 01/2020 - 01/2020
3	Lymphopenia (Lymphocytopenia) 12/2019 - 06/2009
3	Tetanus 01/2018 - 09/2002
3	Persistent Infection 06/2006 - 01/2003
2	COVID-19 12/2021 - 08/2020
2	Tuberculosis (Tuberculoses) 06/2021 - 01/2017
2	Pneumonia (Pneumonitis) 01/2019 - 01/2002
2	Fibrosis (Cirrhosis) 01/2018 - 01/2018
2	Mumps 04/2013 - 05/2002
2	Hepatitis C 01/2011 - 09/2007
2	Thrombosis (Thrombus) 11/2010 - 01/2010
2	Opportunistic Infections (Opportunistic Infection) 06/2010 - 08/2006
2	Hepatitis A (Hepatitis, Infectious) 11/2005 - 01/2003
2	Hypersensitivity (Allergy) 09/2003 - 06/2003
2	Hypergammaglobulinemia (Hyperimmunoglobulinemia) 09/2003 - 01/2002
1	Anemia 01/2022
1	Body Weight (Weight, Body) 12/2021

Drug/Important Bio-Agent (IBA)

18	RNA (Ribonucleic Acid)IBA 03/2019 - 04/2002
17	CytokinesIBA 12/2021 - 01/2002
16	Biomarkers (Surrogate Marker)IBA 01/2022 - 08/2013
12	VaccinesIBA 01/2018 - 01/2003
11	Lipopolysaccharide ReceptorsIBA 01/2021 - 09/2012
11	Interleukin-6 (Interleukin 6)IBA 01/2021 - 06/2010
10	AntigensIBA 01/2018 - 09/2002
8	Proteins (Proteins, Gene)FDA Link 12/2021 - 02/2003
7	LipidsIBA 01/2017 - 09/2007
6	oxidized low density lipoproteinIBA 01/2020 - 04/2014
6	fibrin fragment D (D-dimer)IBA 01/2019 - 01/2013
6	Interleukin-7 (Interleukin 7)IBA 01/2017 - 06/2009
6	InterferonsIBA 11/2016 - 12/2010
6	Thromboplastin (Tissue Factor)IBA 11/2014 - 01/2010
6	Interleukin-2 (IL2)IBA 12/2010 - 01/2003
5	LigandsIBA 10/2016 - 04/2004
4	C-Reactive ProteinIBA 01/2019 - 10/2013
4	Maraviroc FDA Link 01/2017 - 10/2010
4	LDL CholesterolIBA 01/2017 - 10/2013
4	Raltegravir Potassium FDA Link 01/2017 - 08/2010
4	Anti-Infective Agents (Microbicides)IBA 05/2009 - 05/2006
4	Antiviral Agents (Antivirals)IBA 01/2007 - 05/2002
3	efavirenz (Sustiva)FDA Link 12/2021 - 10/2010
3	KynurenineIBA 06/2021 - 07/2013
3	Tryptophan (L-Tryptophan)FDA Link 06/2021 - 07/2013
3	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 11/2014
3	Interleukin-15 (Interleukin 15)IBA 01/2020 - 01/2016
3	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 01/2019 - 10/2014
3	Fibrinogen (Factor I)FDA Link 01/2019 - 04/2014
3	1-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)IBA 01/2017 - 08/2015
3	NucleosidesIBA 01/2016 - 05/2002
3	LipopolysaccharidesIBA 11/2014 - 04/2009
3	Interferon Type IIBA 10/2014 - 05/2009
3	Peptides (Polypeptides)IBA 05/2014 - 08/2006
3	Pharmaceutical PreparationsIBA 01/2013 - 10/2004
3	Cyclosporine (Ciclosporin)FDA LinkGeneric 11/2009 - 04/2002
3	Tetanus Toxoid (Vaccine, Tetanus)FDA Link 09/2003 - 02/2002
2	ruxolitinibIBA 01/2022 - 12/2021
2	Angiotensin Receptor AntagonistsIBA 08/2020 - 01/2018
2	Interferon-gamma (Interferon, gamma)IBA 01/2019 - 08/2006
2	HLA-DR Antigens (HLA-DR)IBA 01/2019 - 01/2015
2	EnzymesIBA 10/2016 - 08/2006
2	Type I Tumor Necrosis Factor ReceptorsIBA 10/2016 - 01/2013
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 05/2016 - 09/2007
2	Reverse Transcriptase InhibitorsIBA 01/2016 - 05/2002
2	Integrase InhibitorsIBA 08/2015 - 01/2015
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/2015 - 06/2010
2	Rosuvastatin Calcium (Crestor)FDA Link 04/2015 - 02/2014
2	Chemokine ReceptorsIBA 11/2014 - 06/2003
2	5P12-RANTESIBA 10/2013 - 05/2009
2	ChemokinesIBA 10/2013 - 11/2010
2	Messenger RNA (mRNA)IBA 01/2013 - 11/2008
2	Interferon-alpha (Interferon Alfa)IBA 01/2012 - 06/2006
2	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2011 - 04/2004
2	InterleukinsIBA 06/2010 - 01/2003
2	PerforinIBA 05/2010 - 01/2003
2	Biological ProductsIBA 06/2009 - 07/2003
2	AntibodiesIBA 11/2005 - 02/2003
1	Immune Checkpoint ProteinsIBA 03/2022
1	Janus Kinase InhibitorsIBA 01/2022
1	BradykininIBA 12/2021
1	Janus Kinase 1IBA 12/2021
1	Cytochrome P-450 CYP3AIBA 12/2021
1	Carbon MonoxideIBA 01/2021
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 08/2020
1	CD58 Antigens (LFA-3)IBA 01/2020
1	Viral ProteinsIBA 01/2020
1	Fingolimod Hydrochloride (FTY720)FDA Link 10/2019

Therapy/Procedure

42	Therapeutics 03/2022 - 01/2002
29	Art Therapy 01/2022 - 11/2006
14	Highly Active Antiretroviral Therapy (HAART) 01/2016 - 02/2002
2	Drug Therapy (Chemotherapy) 07/2009 - 05/2002